Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells ...

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% ...

sBLA accepted for Priority Review Rezpegaldesleukin (Nektar Therapeutics) Selective regulatory T cell (Tregs ... Anti-programmed death receptor-1 (PD-1) therapy For the treatment of patients ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline ... treating disease by modifying the activity of regulatory T cells, or Tregs. Pandion’s lead candidate PT101 ...

Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures -- UDENYCA® net revenue increased 62% year-over-year -- LOQTORZI® net revenue increased 29% quarter-over-qua ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...